Clinical Trial Finder

Inclusion Criteria Informed Consent and Willingness to Participate.

• - 1.

Documented informed consent of the participant and/or legally authorized representative. Assent, when appropriate, will be obtained per institutional guidelines.

• - 2.

Agreement to allow the use of archival tissue from diagnostic tumor biopsies. If unavailable, exceptions may be granted with Study PI approval. Age Criteria, Performance status.

• - 3.

Ages ≥18 years.

• - 4.

KPS ≥ 60%, ECOG ≤ 2.

• - 5.

Life expectancy ≥ 4 weeks Nature of Illness and Illness Related Criteria.

• - 6.

Histologically confirmed diagnosis of WHO classification grade IV GBM, or has a prior histologicallyconfirmed diagnosis of a grade II or III glioma and now has radiographic progression consistent with a grade IV GBM after completing standard therapy.

• - 7.

Relapsed/refractory disease: radiographic evidence of recurrence/progression of measurable disease after standard therapy, and ≥ 12 weeks after completion of front-line radiation therapy.

• - 8.

COH Clinical Pathology confirms IL13Rα2+ tumor expression by IHC at the initial tumor presentation or recurrent disease (H-score > 50; reference Appendix B)

• - 9.

Participants with a known history of congestive heart failure (CHF) or cardiac symptoms consistent with NYHA classification III-IV within 6 months prior to Day 1 of protocol treatment, cardiomyopathy, myocarditis, Myocardial Infarction (MI), exposure to cardiotoxic medications or with clinical history suggestive of the above must have an EKG and Echocardiogram (ECHO) performed within 42 days prior to registration and as clinically indicated while on treatment. Clinical Laboratory and Organ Function Criteria (To be performed within 14 days prior to leukapheresis unless otherwise stated.

• - 10.

WBC > 2000 /dl (or ANC ≥ 1,000/mm3)

• - 11.

Platelets ≥ 75,000/mm3.

• - 12.

Fasting Blood glucose within ULN.

• - 13.

Total bilirubin ≤ 1.5 ULN.

• - 14.

AST ≤ 2.5x ULN.

• - 15.

ALT ≤ 2.5x ULN.

• - 16.

Serum creatinine ≤1.6 mg/dL.

• - 17.

O2 saturation ≥ 95% on room air.

• - 18.

Seronegative for HIV Ag/Ab combo, Hepatitis C Ab*, active HBV (Surface Antigen Negative), Hepatitis A Virus IgM Antibody. *If positive, Hepatitis C RNA quantitation must be performed.

• - 19.

Women of childbearing potential (WOCBP): negative urine or serum pregnancy test If the urine test is positive or cannot be.

• - 20.

Agreement by females and males of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 5 months after the last dose of nivolumab and/or 3 months after the last cycle of CAR T cells. Exclusion Criteria Prior and concomitant therapies.

• - 1.

Prior CTLA-4, PD-1 or PD-L1 inhibitor therapy.

• - 2.

Participant is steroid-dependent, requiring more than 6 mg of dexamethasone per day at the time of enrollment.

• - 3.

Participant has not yet recovered from toxicities of prior therapy. Other illnesses or conditions.

• - 4.

History of or active autoimmune disease.

• - 5.

Uncontrolled seizure activity and/or clinically evident progressive encephalopathy.

• - 6.

History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent.

• - 7.

Active diarrhea.

• - 8.

Clinically significant uncontrolled illness.

• - 9.

Active infection requiring antibiotics.

• - 10.

Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection.

• - 11.

Other active malignancy.

• - 12.

Females only: Pregnant or breastfeeding.

• - 13.

Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures. Noncompliance.

• - 14.

Prospective participants who, in the opinion of the Investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).

PRIMARY OBJECTIVES:

• I. To examine and describe the safety and feasibility of nivolumab plus ipilimumab as neoadjuvant therapy.

(Arm 1)

• II. To examine and describe the safety and feasibility of IL13Ralpha2-CAR T cell plus nivolumab as adjuvant therapy.

(Arms 1 and 2)

• III. To provide IL13Rα2-CAR T cell therapy for subjects who are unable to wait for randomization into Arms 1 and 2.

This arm will provide additional safety data provided in COH IRB 13384 for the set dose schedule. (Arm 3)

• III. In arms determined to be safe and feasible, a selection design based on two Southwest Oncology Group (SWOG) two stage designs will be used to assess which arm(s) goes on for further study based on survival rate at 9 months.

SECONDARY OBJECTIVES:

• I. Describe persistence, expansion and phenotype of endogenous and IL13Ralpha2-CAR CAR T cells in tumor cyst fluid (TCF), peripheral blood (PB), and cerebral spinal fluid (CSF).

• II. Describe cytokine levels (PB, TCF, CSF) over the study period for each arm.

(Arm 1 or Arm 2).

• III. Estimate disease response rates.

• IV. Estimate time to progression.

• V. Estimate median overall survival (OS).

• VI. In study participants who have completed the adjuvant dose-limiting toxicity (DLT) period: VIa.

Estimate the mean change from baseline in quality of life using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core (QLQ-C)30 and EORTC QLQ Brain Cancer Patients (BN-20) survey scale, domain and item scores during and post treatment. VIb. Assess if the area under the curve (AUC) for CD3 T cells, IFNgamma and IP-10 for the DLT period is greater in one arm versus (vs.#46;) the other.

• VII. In study participants who undergo an additional biopsy/resection or autopsy: VIIa.

Evaluate CAR T cell persistence in the tumor tissue and the location of the CAR T cells with respect to the injection, and VIIb. Evaluate IL13Ralpha2 antigen and PD-L1 levels on tumor tissue pre and post CAR T cell therapy.

• VIII. Use biomathematical modeling of tumor growth to evaluate benefit of treatment.

OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive nivolumab intravenously (IV) over 60 minutes and ipilimumab IV over 90 minutes on day -14. Patients then receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (intracranial intraventricular [ICV]/intracranial intratumoral [ICT]) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist. ARM II: Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/ICT) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist. ARM III: Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (intracranial intraventricular [ICV]/intracranial intratumoral [ICT]) every week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly at the discretion of the principal investigator and oncologist. After completion of study treatment, patients are followed up at 30 days, 3, 6, and 12 months, and then annually for 15 years.

Arms

Experimental: Arm I (nivolumab, ipilimumab, IL13Ralpha2 CAR T cells)

Patients receive nivolumab intravenously (IV) over 60 minutes and ipilimumab IV over 90 minutes on day -14. Patients then receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/intracranital ICT) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.

Experimental: Arm II (nivolumab, IL13Ra2 CAR T cells)

Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/ICT) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.

Experimental: Arm III (IL13Ra2 CAR T cells)

Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/ICT) every week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly at the discretion of the principal investigator and oncologist.

Interventions

Biological: - IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells

Given ITV/ITC

Biological: - Ipilimumab

Given IV

Biological: - Nivolumab

Given IV

Other: - Quality-of-Life Assessment

Ancillary studies

Other: - Questionnaire Administration

Ancillary studies